Compass Pathways PLC

Compass Pathways announced positive 26-week results from its Phase 3 COMP006 trial for COMP360 in treatment-resistant depression, showing rapid onset and durable efficacy.

COMPASS Pathways shareholders re-elected board members and approved executive compensation at the 2026 Annual General Meeting.

Compass Pathways reported strong Q1 2026 results, highlighted by FDA granting rolling submission for COMP360 and a significant increase in cash reserves.

Compass Pathways announced its full-year 2025 financial results and significant progress in its COMP360 clinical programs for TRD and PTSD, extending its cash runway into 2028.

COMPASS Pathways plc announced the pricing of a public offering totaling $150.0 million, including ADSs and pre-funded warrants, to fund its clinical trials and operations.

Compass Pathways plc announced highly statistically significant positive topline results from its second pivotal Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression, alongside consistent safety data.

Compass Pathways plc announced its first quarter 2026 financial results, highlighting significant progress in its Phase 3 clinical trials for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), alongside a substantial increase in cash reserves.

COMPASS Pathways reported a significant increase in net loss for Q3 2025, driven by warrant liability revaluation, while advancing its COMP360 psilocybin treatment in Phase 3 trials for TRD and a late-stage program for PTSD.

COMPASS Pathways announced positive top-line primary endpoint data from its first Phase 3 trial for treatment-resistant depression (TRD) and extended its cash runway into 2027, despite ongoing operating losses.

Compass Pathways amends its research collaboration agreement with Kings College London and South London and Maudsley NHS Foundation Trust, and files its Q1 2025 report, highlighting financial strategies and clinical trial advancements.

COMPASS Pathways announces its third quarter 2024 financial results alongside a strategic reorganization to focus on its Phase 3 program for treatment-resistant depression.

COMPASS Pathways reports a net loss of $73.3 million for the first half of 2024, while highlighting progress in its Phase 3 clinical program for COMP360 psilocybin treatment.

COMPASS Pathways reports positive Phase 3 results for COMP360 psilocybin in TRD, initiates PTSD trial, and strengthens financial position with recent capital raises.

COMPASS Pathways plc files its 10-K, highlighting progress in its Phase 3 program for COMP360 and plans for a late-stage PTSD program.

COMPASS Pathways appoints an interim CFO, Mary-Rose Hughes, and outlines her compensation, while also filing its annual report on Form 10-K, detailing financial performance and future outlook.

Director Daphne Karydas was granted 21,110 stock options in COMPASS Pathways plc as part of standard equity compensation.

Director Gino Santini was granted 30,158 share options in COMPASS Pathways plc as part of an equity compensation arrangement.

Director Justin Gover was granted 21,110 share options in COMPASS Pathways plc as part of a standard equity compensation arrangement.

Director Jeffrey M. Jonas was granted 21,110 stock options in COMPASS Pathways plc as part of a standard equity compensation award.

COMPASS Pathways plc director Wayne Riley was granted 21,110 stock options as part of standard equity compensation.

Director Robert McQuade was granted 21,110 share options in COMPASS Pathways plc as part of an equity compensation award.

COMPASS Pathways plc has issued its proxy statement for the 2026 Annual General Meeting to be held on May 27, 2026.

COMPASS Pathways is holding its 2025 Annual General Meeting to vote on director re-elections, auditor appointments, executive compensation, and authorization for future share allotments.

COMPASS Pathways is holding its 2024 Annual General Meeting on May 9, 2024, to vote on important resolutions including director re-elections, auditor appointments, and share allotment authorizations.

ATAI Life Sciences N.V. reported a reduction in its beneficial ownership of COMPASS Pathways plc to 6.0% following recent open market sales.

ATAI Life Sciences N.V. and its subsidiary ATAI Life Sciences AG have filed an Amendment No. 4 to Schedule 13D, disclosing a beneficial ownership of 7.5% in COMPASS Pathways plc as of March 5, 2025.

RTW Investments, LP and Roderick Wong have disclosed a beneficial ownership of 9.9% of COMPASS Pathways plc's ordinary shares, holding 12,971,571 shares.

Vivo Opportunity Fund Holdings and affiliates reported a combined 3.4% beneficial ownership in COMPASS Pathways plc, primarily through warrants.

Nantahala Capital Management and its principals have reduced their beneficial ownership in COMPASS Pathways plc to 3.57% of the outstanding American Depositary Shares.

RTW Investments and Roderick Wong have disclosed a 9.99% beneficial ownership stake in COMPASS Pathways plc, including shares from warrant exercise.

TCG Crossover Funds and Chen Yu report beneficial ownership of Compass Pathways plc ordinary shares via warrants, totaling 3.9% for Chen Yu.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 6.23% beneficial ownership stake in COMPASS Pathways plc.